Renin inhibition with aliskiren in hypertension: Focus on aliskiren/hydrochlorothiazide combination therapy

Vascular Health and Risk Management

Volumn 4, Issue 6, 2008, Pages 1205-1220

  Sureshkumar, Kalathil K ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Aliskiren; Aliskiren hydrochlorothiazide; Combination therapy; Hypertension; Renin inhibitors; Renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CIMETIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; MEVINOLIN; PLACEBO; RAMIPRIL; RENIN; VALSARTAN;

ADD ON THERAPY; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; HUMAN; HYPERTENSION; HYPOKALEMIA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL EDEMA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 60249094363     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Aldeman MH, Ooi WI, Cohen H, et al. 1997. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J hypertens, 10:1-18.
2. Andersen K, Weinberger MH, Egan B, et al. 2008. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens, 26:589-99.
3. Azizi M, Menrad J, Bissery A, et al. 2004. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1-receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol, 15:3126-33.
4. Azizi M, Webb R, Nussberger J, et al. 2006. Renin inhibition with aliskiren: where are we now and where are we going? J Hypertens, 24:243-56.
5. Azizi M, Menrad J, Bissery A, et al. 2007. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol, 2:947-55.
6. Chiarelli F, Pomilio M, De Luca FA, et al. 2001. Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr Nephrol, 16:116-20.
7. Chobanian AV, Bakris GL, Black HR, et al. 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension, 42:1206-52.
8. Chrysant SG, Murray AV, Hoppe UC, et al. 2008. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin, 24:1039-47.
9. Cushman WC, Ford CE, Cutler JA, et al. 2002. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hyertens, 4:393-404.
10. Dahlof B, Anderson DR, Arora V, et al. 2007. Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension. J Clin Hypertens, 9 (Suppl A):A157.
11. Danser AH, Derkx FH, Schalekamp MA, et al. 1998. Determinant so finterindividual variation of renin and pro-renin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens, 16:853-62.
12. Danser AHJ, Deinum J. 2005. Renin, pro-renin and the putative (pro)renin receptor. Hypertension, 46:1069-76.
13. Dellipizzi AM, Hilchey SD, Bell-Quilley CP. 1994. Natriuretic action of angiotensin (1-7). Br J Pharmacol, 111:1-3.
14. Dieterle W, Corynen S, Mann J. 2004. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in health subjects. Br J Clin Pharmacol, 58:433-6.
15. Dieterich H, Kemp C, Vaidyanathan S, et al. 2006. Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant interactions with digoxin in healthy volunteers. Clin Pharmacol Ther, 79:111-24.
16. Dieterle W, Corynen S, Vaidyanathan S, et al. 2005. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther, 43:527-35.
17. Drummond W, Munger MA, Essop MR, et al. 2007. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens, 9:742-50.
18. Dzau VJ. 2001. Tissue angiotensin and pathophysiology of vascuklar disease, a unifying hypothesis. Hypertension, 37:1047-52.
19. Feldman DL, Jin L, Xuan H, et al. 2008. Effect of aliskiren on blood pressure, albuminuria, and(pro)renin receptor expression in diabetic TG(mRen-2) rats. Hypertension, 52:130-6.
20. Fisher ND, Hollenberg NK. 2001. Is there a future for renin inhibitors? Exp Opin Invest Drugs, 10:417-26.
21. Fisher ND, Jan Danser AH, Nussberger J, et al. 2008. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation, 117:3199-205.
22. Freeman EJ, Chisolm GM, Ferrario CM, et al. 1996. Angiotensin (1-7) inhibits vascular smooth muscle growth. Hypertension, 28:104-8.
23. Ganten D, Wagner J, Zeh K et al. 1992. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensin genes. Proc Natl Acad Sci USA, 89:7806-10.
24. Gradman AH, Schmieder RE, Lins RL, et al. 2005. Aliksiren, a novel orally effective renin inhibitir, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation, 111:102-8.
25. Hollenberg NK, Fisher ND, Price DA. 1998. Pathways of angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension, 32:387-92.
26. Iyer SN, Chappell MC, Averill DB, et al. 1998. Vasodepressor actions of angiotensin (1-7) unmasked during combine treatment with lisinopril and losartan. Hypertension, 31:699-705.
27. Jordan J, Engeli S, Boye SW, et al. 2007. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension, 49:1047-55.
28. Kearney PM, Whelton M, Reynolds K, et al. 2005. Global burden of hypertension: analysis of worldwide data. Lancet, 365:217-23.
29. Kelly DJ, Zhang Y, Moe G, et al. 2007. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia, 50:2398-404.
30. Kim S, Iwao H. 2000. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev, 52:11-34.
31. Kushiro T, Itakura H, Abo Y, et al. 2006. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res, 29:997-1005.
32. Li P, Chappell MC, Ferrario CM, et al. 1997. Angiotensin (1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension, 29:394-400.
33. Luetscher JA, Kraemer FB, Wilson DM, et al. 1985. Increased plasma inactive renin in diabetes mellitus a marker of microvascular complications. N Engl J Med, 312:1412-17.
34. Luque M, Martin P, Martell N, et al. 1996. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens, 14:799-805.
35. Mahon JM, Carr RD, Nicol AK, et al. 1994. Angiotensin (1-7) is an antagonist at the type 1 angiotensin II receptor. J Hypertens, 12:1377-81.
36. Materson BJ, Reda DJ, Cushman WC, et al. 1993. Single drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The department of Veterans Affairs Cooperative Study Group on Antihypertensive agents. N Engl J Med, 328:914-21.
37. Menard J, Aziz M. 2007. The difficult conception, birth and delivery of renin inhibitor: controversies around aliskiren. J Hypertens, 25:1775-82.
38. Novartis Pharmaceuticals Corporation. 2007. Tecturna® (aliskiren tablets): US prescribing information. East Hanover, NJ.
39. Nguyen G, Delarue F, Burckle C, et al. 2002. Pivotal role of the renin/ pro-renin receptor in angiotensin II production and cellular responses to renin. J Clin Invest, 109:1417-27.
40. Nussbeger J, Wuerzner G, Jensen C, et al. 2002. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100); Comparison with enalapril. Hypertension, 39:E1-8.
41. Nussberger J, Aubert JF, Bouzourene K, et al. 2008. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension, 51:1306-11.
42. O'Brien E, Barton J, Nussberger J, et al. 2007. Aliskiren reduced blood pressure and suppress plasma renin activity in combination with a thiazide diuretic, an angiotensin converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension, 49:276-84.
43. Oh BH, Mitchell J, Herron JR, et al. 2007. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol, 49:1157-63.
44. Ong KL, Cheung BM, Man YB, et al. 2007. Prevalence, awareness, treatment and control of hypertension among United States adults 1999-2004. Hypertension, 49:69-75.
45. Oparil S, Haber E. 1974. The renin angiotensin system. N Engl J Med, 291:381-401.
46. Oparil S, Yarows SA, Patel S, et al. 2007. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet, 370:221-9.
47. Parving HH, Persson F, Lewis JB, et al. 2008. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med, 358:2433-46.
48. Philips MI, Speakman EA, Kimura B. 1993. Levels of angiotensin and molecular biology of the tissue angiotensin systems. Regul Pept, 43:1-20.
49. Pilz B, Shagdarsuren E, Wellner M, et al. 2005. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension, 46:569-76.
50. Pool JL, Schmieder RE, Azizi M, et al. 2007. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens, 20:11-20.
51. Sarris JJ, 't Hoen PAC, Garrelds IM, et al. 2006. Pro-renin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension, 48:564-71.
52. Shagdarsuren E, Wellner M, Braesen JH, et al. 2005. Compliment activation in angiotensin II induced organdamge. Circ Res, 97:716-24.
53. Schefe JH, Neumann C, Goebel M, et al. 2008. Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren. J Hypertens, 26:1787-94.
54. Schmieder RE. 2007. The potential role of pro-renin in diabetic nephropathy. J Hypertens, 25:1323-6.
55. Schmieder RE, Philipp T, Guerediaga J, et al. 2007. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in patients with hypertension. J Clin Hypertens, 9(Suppl A):A182.
56. Sealey JE, Laragh JH. 2007. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens, 20:587-97.
57. Sica D, Gradman A, Lederballe O, et al. 2006. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J, 27(Suppl):A797.
58. Siragy HM, Xue C, Abadir P, et al. 2005. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. Hypertension, 45:133-7.
59. Skolnik NS, Beck JD, Clark M. 2000. Combination antihypertensive drugs: recommendations for use. Am Fam Physician, 61:3049-56.
60. Smithies O. 1997. Theodore Cooper Memorial Lecture. A mouse view of hypertension. Hypertension, 30:1318-24.
61. Stanton A, Jensen C, Nussberger J, O'Brien E.2003. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension, 42:1137-43.
62. Strasser RH, Puig JG, Farsang C, et al. 2007. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens, 21:780-7.
63. Takahashi H, Ichihara A, Kaneshiro Y, et al. 2007. Regression of nephropathy developed in diabetes by (pro)renin receptor blockade. J Am Soc Nephrol, 18:1989-92.
64. Urata H, Kinoshita A, Misono KS, et al. 1990. Identification of a highly specific chymase as the major angiotensin II forming enzyme in the human heart. J Biol Chem, 265:22348-57.
65. Uresin Y, Taylor AA, Kilo C, et al. 2007. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst, 8:190-8.
66. Vaidyanathan S, Velencia J, Kemp C, et al. 2006. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract, 60:1343-56.
67. Vaidyanathan S, Reynolds C, Yeh CM, et al. 2007. Pharmacokinetics, safety and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol, 47:453-60.
68. Verdecchia P, Calvo C, Mockel V, et al. 2007. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press, 16:381-91.
69. Villamil A, Chrysant SG, Calhoun D, et al. 2007. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens, 25:217-26.
70. Waeber B. 2003. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretic in hypertension. Expert Rev Cardiovascular Ther, 1: 43-50.
71. Waldmeier FJ, Glaenzel U, Wirz B, et al. 2007. Absorption, distribution, metabolism and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos, 35:1418-28.
72. Wantanabe T, Barker TA, Berk BC. 2005. Angiotensin II and the endothelium: diverse signals and effects. Hypertension, 45:163-9.
73. Weir MR, Bush C, Anderson DR, et al. 2007. Antihypertensive efficacy, safety, and tolrability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens, 1:264-77.
74. Williams B. 2001. Angiotensin II and the pathophysiology of cardiovascular remodeling. Am J Cardiol, 87:10C-17C.
75. Whaley-Connell A, Habibi J, Cooper SA, et al. 2008. Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab.
76. Wolf-Maier K, Cooper RS, Kramer H, et al. 2004. Hypertension treatment and control in five European countries, Canada and the United States. Hypertension, 43:10-7.
77. Wood JM, Mailbaum J, Rahuel J, et al. 2003. Structure based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun, 308:698-705.